1. Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis
- Author
-
Xu Wang, Yoel Genaro Montoyo-Pujol, Miguel A. López-Nevot, Francisco Almazan, Aurelio Martin, Gonzalo Corpas, Teresa Cabrera, Sandra Bermudez, [Wang,X, Montoyo-Pujol,YG, Bermudez,S, Corpas,G, López-Nevot,MA] Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de Las Nieves, Granada, Spain. [Wang,X] Programa de Doctorado en Biomedicina, Universidad de Granada, Granada, Spain. [Martin,A] Servicio de Anatomía Patológica, Hospital Universitario Virgen de Las Nieves, Granada, Spain. [Almazan,F] Servicio de Dermatología, Hospital Universitario Clínico San Cecilio (PTS), Granada, Spain. [Cabrera,T, López-Nevot,MA] Departamento Bioquímica, Biología Molecular e Inmunología III, Universidad de Granada, Granada, Spain. [López-Nevot,MA] Instituto de Investigación Biosanitaria I Ibs. GRANADA, Granada, Spain., and This work was supported by Instituto de Salud Carlos II (FISS PI 13/02119).
- Subjects
0301 basic medicine ,Eotaxin ,Oncology ,Chemokine ,medicine.disease_cause ,Metastasis ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Immunologic Techniques::Immunoassay [Medical Subject Headings] ,Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Nerve Growth Factors::Brain-Derived Neurotrophic Factor [Medical Subject Headings] ,Quimiocinas ,0302 clinical medicine ,Medicine ,Melanoma ,RC254-282 ,Mutation ,biology ,Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukin 1 Receptor Antagonist Protein [Medical Subject Headings] ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Citocinas ,Factor de crecimiento epidérmico ,Vascular endothelial growth factor A ,Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Angiogenic Proteins::Vascular Endothelial Growth Factors::Vascular Endothelial Growth Factor A [Medical Subject Headings] ,030220 oncology & carcinogenesis ,Cytokines ,Chemokines ,Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Epidermal Growth Factor [Medical Subject Headings] ,Research Article ,medicine.medical_specialty ,Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings] ,Article Subject ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Control Groups [Medical Subject Headings] ,Brain-derived neurotrophic factor ,Breslow Thickness ,03 medical and health sciences ,Factor neurotrófico derivado del encéfalo ,Internal medicine ,Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Cycle::Cell Division::Cytokinesis [Medical Subject Headings] ,Diseases::Neoplasms::Neoplasms by Histologic Type::Nevi and Melanomas::Melanoma [Medical Subject Headings] ,EGF ,Factor A de Crecimiento Endotelial Vascular ,business.industry ,Epidermal growth factor ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Chemokines [Medical Subject Headings] ,medicine.disease ,Serum cytokine ,BDNF ,030104 developmental biology ,Check Tags::Female [Medical Subject Headings] ,Tumor progression ,biology.protein ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings] ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Neoplasm Proteins::Oncogene Proteins::Proto-Oncogene Proteins::raf Kinases::Proto-Oncogene Proteins B-raf [Medical Subject Headings] ,business ,Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-7 [Medical Subject Headings] - Abstract
Purpose. Previous studies have shown that melanoma cells produce excessive levels of cytokines, which have various biological roles during melanoma development. The aim of this study was to expand the profile of serum cytokines, chemokines, growth factors, and angiogenic factors that are associated with melanoma, to find more cytokines with abnormal concentrations in melanoma patients, to identify whether the level of cytokines correlated with prognostic variants, such as Breslow thickness and BRAF mutation, and, finally, to find out the cytokines that play important roles during melanoma development. Materials and Methods. Multiplex immunobead assay technology and 45-plex immunoassays ProcartaPlex (TM) kits were used to simultaneously compare the levels of cytokines, growth factors, angiogenic factors, and chemokines between the serum of healthy patients (n = 30) and those with melanoma (n = 72). Data were analyzed according to the clinical characteristics of the designated patient subgroups. Results. Compared to the control group, melanoma patients had higher levels of VEGF-A, PDGF-BB, IL-1RA, PIGF-1, IFN-gamma, TNF-alpha, MIP-1 alpha, and SCF, but lower levels of BDNF, SDF-1 alpha, MCP-1, Eotaxin, EGF, and IL-7. Furthermore, the levels of TNF-alpha (P=0.320, r = 0.019), IFN-gamma (P=0.311, r = 0.023), VEGF-A (P=0.014, r = 0.337), and BDNF (0.004, r = -0.391) showed a significant correlation with Breslow thickness. IL-7 was of lower levels in patients harboring BRAF mutants. Melanoma patients with high levels of MIP-1 alpha and MCP-1 showed the poorest overall survival. Conclusions. We found that the levels of VEGF-A and PDGF-BB in the serum of both primary and metastatic melanoma patients are elevated. TNF-alpha, IFN-gamma, and VEGF-A presented a positive correlation with Breslow thickness, whereas BDNF showed a negative association. MIP-1 alpha and MCP-1 correlated negatively with survival. In addition, lower levels of IL-7 were found in patients harboring BRAF mutants. These findings indicate that these cytokines may play critical roles in the progression of melanoma., Instituto de Salud Carlos II FISS PI 13/02119
- Published
- 2021